Lakewood-Amedex Advances Nu-3 into Phase 2a Trial for Diabetic Foot Ulcers
Event summary
- Lakewood-Amedex received IRB approvals to begin Phase 2a trial of Nu-3 for infected diabetic foot ulcers.
- Trial will evaluate safety and efficacy of Nu-3, a topical gel with a unique antimicrobial mechanism.
- Study chaired by diabetic foot ulcer expert Dr. David G. Armstrong.
- Nu-3 targets drug-resistant wound infections, aligning with PACCARB mandates.
The big picture
Lakewood-Amedex's Phase 2a trial initiation positions Nu-3 as a potential solution for a growing public health challenge: diabetic foot ulcers, which affect millions and often lead to amputations. The trial comes amid increasing global concern over antimicrobial resistance, with governments and health organizations prioritizing innovative therapies that evade resistance mechanisms. Success here could validate the company's Bisphosphocin® platform as a key player in the fight against resistant bacterial strains.
What we're watching
- Clinical Efficacy
- Whether Nu-3 can demonstrate superior wound healing and antimicrobial response in human trials compared to preclinical results.
- Regulatory Alignment
- How closely Lakewood-Amedex can maintain alignment with PACCARB guidelines while advancing Nu-3 through development.
- Market Differentiation
- The pace at which Nu-3 can establish itself as a viable alternative to existing treatments for drug-resistant wound infections.
Related topics